Journal
NATURE MEDICINE
Volume 19, Issue 3, Pages 291-294Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3101
Keywords
-
Funding
- US National Institutes of Health [DK086956, HL24415]
- American Heart Association postdoctoral fellowship
Ask authors/readers for more resources
Enhanced fetal gamma-globin synthesis alleviates symptoms of beta-globinopathies such as sickle cell disease and beta-thalassemia, but current gamma-globin-inducing drugs offer limited beneficial effects. We show here that lysine-specific demethylase 1 (LSD1) inhibition by RNAi in human erythroid cells or by the monoamine oxidase inhibitor tranylcypromine in human erythroid cells or beta-type globin-transgenic mice enhances gamma-globin expression. LSD1 is thus a promising therapeutic target for gamma-globin induction, and tranylcypromine may serve as a lead compound for the development of a new gamma-globin inducer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available